- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Coherus Oncology Misses Q1 Earnings Estimates
Biotechnology company reports $0.03 EPS shortfall in latest quarter
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Coherus Oncology (NASDAQ:CHRS), a biopharmaceutical company focused on oncology support and immunotherapy, reported its first-quarter financial results on Monday. The company posted a loss of $0.34 per share, missing the consensus analyst estimate of a $0.31 per share loss by $0.03.
Why it matters
Coherus Oncology's earnings miss highlights the challenges the company faces in developing and commercializing its pipeline of oncology and immunotherapy products. As a smaller biotech firm, Coherus relies on strong financial performance to fund its R&D efforts and maintain investor confidence.
The details
The company reported a net loss of $50.4 million for the quarter, compared to a loss of $45.9 million in the same period a year earlier. Coherus attributed the wider loss to increased spending on research and development as it advances its pipeline of biosimilar and novel oncology treatments.
- Coherus Oncology reported its Q1 2026 financial results on Monday, March 9, 2026.
The players
Coherus Oncology
A commercial-stage biopharmaceutical company focused on developing and commercializing biosimilar and novel oncology treatments.
The takeaway
Coherus Oncology's earnings miss underscores the competitive pressures and high R&D costs facing smaller biotech firms as they work to bring new cancer treatments to market. The company will need to closely manage its expenses and pipeline progress to maintain investor confidence going forward.
